Objective: The aim of this study was to determine the availability of a new liver stiffness (LS) measurement, the elastography point quantification (ElastPQ) method, in non-alcoholic fatty liver disease (NAFLD) and to compare it with other noninvasive Liver fibrosis (LF) investigations. Material and Methods: A total of 108 patients with or without NAFLD were included in this study. LS measurement was done by the ElastPQ method. Noninvasive LF investigations; the AST/ Platelet-ratio-index (APRI), Fibrosis-4 (FIB-4) index, NAFLD fibrosis score, AST/ALT ratio and BARD score were evaluated. Results: Liver size, LS, APRI, FIB-4 index, NAFLD fibrosis score, AST/ALT ratio and BARD score were all significantly higher in NAFLD patients. It was determined that only LS among these parameters independently determined the NAFLD status. It was found that each 0.5-kPa increase in LS increased the risk of having NAFLD 2.12 fold. When the ROC analysis was performed for the NAFLD determination of the LS value, it was determined that the area under the ROC curve was 0.967, and when the limit value for LS was taken as 5-kPa, the risk of having NAFLD was determined with 88.9% sensitivity and 94.4% specificity. Conclusion: The LS value obtained by ElastPQ has high diagnostic accuracy for NAFLD and performs better than other noninvasive laboratory methods in the assessment of NAFLD. At the same time, the LS value is closely related to the FIB-4 index, NAFLD fibrosis score and BARD score.